You are here

Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)

BURLINGAME, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) announced today that the editors of ‘blood’® , which is widely regarded as a premier journal in hematology and the official journal of the American Society of Hematology, selected their study entitled “GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts” and a key image from the associated manuscript for the front cover of the current edition of the journal.  The study was conducted using lenzilumab, the company’s proprietary Humaneered® anti-GM-CSF monoclonal antibody, and the manuscript is available, along with the front cover image, at http://www.bloodjournal.org/content/133/7/697
Friday, February 15, 2019 - 08:00